Mednet Logo
Community

For ALK positive NSCLC, where in treatment sequencing do you utilize lorlatinib?

Does the recent CROWN trial affect your first line treatment decision?
Community PollStarted

Based on the results of the CROWN trial, will you use lorlatinib in all advanced ALK positive NSCLC patients?

70 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Henry Ford Cancer Institute/Henry Ford Hospital
Answered on

The CROWN trial was one of the most important trials reported in the field of lung cancer in 2020. The results of this trial with a median follow up of 18 months were presented by Dr. Ben Solomon at ESMO 2020. The HR for Investigator assessed PFS in this trial with lorlatinib was 0.21 (0.28- Indepen...

Join for free or sign in to see the full answer